Track topics on Twitter Track topics that are important to you
6120 Windward Parkway, Suite 290
United States of America
NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Dan Myers, CEO of Alimera Sciences, updates the success Iluvien is having within the market.
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 9:00 AM Eastern ...
Ophthalmic-focused Alimera Sciences Inc. entered into a $40mm million term loan agreement with Solar Capital. The loan matures on July 1, 2022, carries an interest rate of 9.2%, and is payable at one-...
Alimera Sciences has entered into a $40 million term loan agreement with Solar Capital Ltd., according to a company press release.Alimera plans to use the loan to pay off an existing $35 million term ...
Net Revenue of $9.8 million for the third quarter of 2017 compared to $8.3 million for the third quarter of 2016, an 18% increaseGAAP Net Loss of $5.3 million for the third quarter of 2017 compared...
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today anno...
Alimera Sciences reported a net loss of $7.2 million, or $0.10 per share, in the fourth quarter of 2017 compared with a net loss of $5.9 million, or $0.09 per share, in the same quarter the previous y...
Peer review is an essential part in the publication process, ensuring that Veterinary Sciences maintains high quality standards for its published papers[...].
The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.
C8 sciences program is a cognitive training program mainly developed for the students, and the effectiveness is well established. The aim of this trial is to assess clinical efficacy of th...
Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus S...
The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use...
Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...
Our name, Alimera, is a loose combination of ancient Greek words with the intended meaning of "Day of Truth" and is founded on the underlying principles of honesty, integrity, responsibility, candor, ...
DVS Sciences is a life sciences technology company that has developed and manufactures a novel technology for highly multiplexed analysis of single cells. DVS Sciences has an R&D ...
Origin Sciences is a medical technology company developing innovative devices and tests to aid the detection and diagnosis of gastrointestinal diseases. Origin Sciences is based i...
T.A. Sciences www.TASciences.com is the first company in the world to offer its clients the ability to fight aging through the emerging science of telomere biology. T.A. Sciences was founded by Noel T...
We have published hundreds of Alimera Sciences news stories on BioPortfolio along with dozens of Alimera Sciences Clinical Trials and PubMed Articles about Alimera Sciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alimera Sciences Companies in our database. You can also find out about relevant Alimera Sciences Drugs and Medications on this site too.